MedTrace Logo

Levels of Inflammatory Markers in the Treatment of Stroke-An SPS3 Ancillary Study

NCT00579306 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1244

Last updated 2017-07-24

No results posted yet for this study

Summary

The goals of this trial are to determine the prognostic significance of an elevated level of inflammatory blood markers in people who have experienced small subcortical strokes and who are enrolled in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.

Conditions

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Columbia University

    lead OTHER

Principal Investigators

  • Mitchell S. Elkind, MD, MS, FAAN · Columbia University

  • Oscar Benavente, MD · UTHSC San Antonio (SPS3 Principal Investigator)

  • Robert Hart, MD · UTHSC San Antonio (SPS3 Principal Investigator)

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2012-04-30
Completion
2012-07-31

Countries

  • United States
  • Canada
  • Chile
  • Ecuador
  • Mexico
  • Peru
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00579306 on ClinicalTrials.gov